CD34 and neoplasm: To further assess the capacity of our model to depict changes in tumor vascularization, we investigated the micro-angioarchitectural modifications occurring in KMS-11 lesions following the administration of CD34+ cells engineered to express membrane-bound TRAIL (CD34−TRAIL+ cells)25.